"PEH" redirects here. For other uses, see Peh (disambiguation).

Phenylethylidenehydrazine (PEH), also known as 2-phenylethylhydrazone or β-phenylethylidenehydrazine, is a GABA transaminase inhibitor.[1][2] It is a metabolite of the antidepressant phenelzine and is responsible for its elevation of GABA concentrations.[1] PEH may contribute to phenelzine's anxiolytic effects.[3]

See also

References

  1. ^ a b Parent MB, Master S, Kashlub S, Baker GB (January 2002). "Effects of the antidepressant/antipanic drug phenelzine and its putative metabolite phenylethylidenehydrazine on extracellular gamma-aminobutyric acid levels in the striatum". Biochemical Pharmacology. 63 (1): 57–64. doi:10.1016/S0006-2952(01)00856-5. PMID 11754874.
  2. ^ Duffy S, Nguyen PV, Baker GB (2004). "Phenylethylidenehydrazine, a novel GABA-transaminase inhibitor, reduces epileptiform activity in rat hippocampal slices". Neuroscience. 126 (2): 423–432. doi:10.1016/j.neuroscience.2004.03.007. PMID 15207360. S2CID 30625470.
  3. ^ Baker GB, Wong JT, Yeung JM, Coutts RT (March 1991). "Effects of the antidepressant phenelzine on brain levels of gamma-aminobutyric acid (GABA)". Journal of Affective Disorders. 21 (3): 207–211. doi:10.1016/0165-0327(91)90041-p. ISSN 0165-0327. PMID 1648582.